{
  "id": "64240f33690f196b51000049",
  "type": "list",
  "question": "What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?",
  "ideal_answer": "Drugs used to treat Feline Infectious Peritonitis (FIP) in cats include immune suppressive drugs such as prednisone or cyclophosphamide, recombinant feline interferon, glucocorticoids, antibiotics, passive immunization with Feliserin, Propentofylline (PPF), Polyprenyl Immunostimulant, antiviral RNAi, viroporin inhibitors, a broad-spectrum coronavirus protease inhibitor GC376, anti-feline TNF-alpha monoclonal antibody, the adenosine nucleoside analogue GS-441524, mefloquine, itraconazole, and remdesivir.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32441826",
    "http://www.ncbi.nlm.nih.gov/pubmed/30755068",
    "http://www.ncbi.nlm.nih.gov/pubmed/35934910",
    "http://www.ncbi.nlm.nih.gov/pubmed/15123155",
    "http://www.ncbi.nlm.nih.gov/pubmed/32220667",
    "http://www.ncbi.nlm.nih.gov/pubmed/32456286",
    "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
    "http://www.ncbi.nlm.nih.gov/pubmed/27027316",
    "http://www.ncbi.nlm.nih.gov/pubmed/36297266",
    "http://www.ncbi.nlm.nih.gov/pubmed/34835034",
    "http://www.ncbi.nlm.nih.gov/pubmed/31585653",
    "http://www.ncbi.nlm.nih.gov/pubmed/29778200",
    "http://www.ncbi.nlm.nih.gov/pubmed/32848107",
    "http://www.ncbi.nlm.nih.gov/pubmed/22092616",
    "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
    "http://www.ncbi.nlm.nih.gov/pubmed/25596968",
    "http://www.ncbi.nlm.nih.gov/pubmed/26850532",
    "http://www.ncbi.nlm.nih.gov/pubmed/32521771",
    "http://www.ncbi.nlm.nih.gov/pubmed/35078478",
    "http://www.ncbi.nlm.nih.gov/pubmed/18395801",
    "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
    "http://www.ncbi.nlm.nih.gov/pubmed/25701212",
    "http://www.ncbi.nlm.nih.gov/pubmed/33799985"
  ],
  "snippets": [
    {
      "text": "s FIP is an immune-mediated disease, treatment is mainly aimed at controlling the immune response triggered by the infection with the feline coronavirus (FCoV). Immune suppressive drugs such as prednisone or cyclophosphamide may slow disease progression but do not produce a cure. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18395801",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A total of 12 clinically ill cats previously diagnosed as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15123155",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "YPOTHESIS: Feline interferon-omega (FeIFN-omega) prolongs survival time and increases quality of life in cats with FIP.ANIMALS:",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats with FIP, and increase their quality of life.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, PPF does not appear to be an effective treatment option in cats with a late stage of the disease FIP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Feline infectious peritonitis (FIP) is considered a fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive and well 2 years after diagnosis. The third cat survived 14 months but was treated for only 4.5 months. Further studies are necessary to assess the potential of the Polyprenyl Immunostimulant.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritoniti",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Feline infectious peritonitis (FIP) is a highly fatal disease caused by a virulent feline coronavirus in domestic and wild cats. We have previously reported the synthesis of potent coronavirus 3C-like protease (3CLpro) inhibitors and the efficacy of a protease inhibitor, GC376, in client-owned cats with FIP. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31585653",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combination siRNA therapy against feline coronavirus can delay the emergence of antiviral resistance in vitro.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25596968",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "these data inform the potential therapeutic application of antiviral RNAi against FIPV.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25596968",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We previously reported the successful in vitro inhibition of FIPV replication by synthetic siRNA mediated RNA interference (RNAi) in an immortalised cell line (McDonagh et al., 2011).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25596968",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Differential effects of viroporin inhibitors against feline infectious peritonitis virus serotypes I and II.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701212",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " However, it is not clear whether HMA and other viroporin inhibitors affect replication of FIPV. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e examined the effect of HMA and other viroporin inhibitors (DIDS [4,4'-disothiocyano-2,2'-stilbenedisulphonic acid] and amantadine) on infection by FIPV serotypes I and II. HMA treatment drastically decreased the titers of FIPV serotype I strains Black and KU-2 in a dose-dependent manner, but it only slightly decreased the titer of FIPV serotype II strain 79-1146",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In contrast, DIDS treatment decreased the titer of FIPV serotype II strain 79-1146 in dose-dependent manner, but it only slightly decreased the titers of FIPV serotype I strains Black and KU-2. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27027316",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here, we evaluated the therapeutic efficacy of our 3CLpro inhibitor in laboratory cats with FIP. Experimental FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be otherwise fatal if left untreated",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27027316",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therapeutic effect of anti-feline TNF-alpha monoclonal antibody for feline infectious peritonitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850532",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These results strongly suggested that the anti-fTNF-alpha antibody is effective for the treatment of FIP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850532",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32441826",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Treatment with GS-441524 shows clinical efficacy and may result in clearance and long-term resolution of neurological FIP",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32441826",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mutian\u00ae Xraphconn (Mutian X) is a product marketed to treat cats with FIP but is also being used to stop virus shedding, although no clear guidelines exist for its use for this purpose. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32220667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oral Mutian\u00aeX stopped faecal feline coronavirus shedding by naturally infected cats.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32220667",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32521771",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The pharmacokinetic profile of mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections (such as feline infectious peritonitis) or feline calicivirus infections",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32521771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus infections in cats.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32521771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, itraconazole partly exerted a beneficial effect in a cat with FIP. However, further investigation of a possible role of itraconazole in FIP treatment is warranted.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32848107",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32848107",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755068",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755068",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "S-441524 was shown to be a safe and effective treatment for FIP. The optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755068",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This paper reports on the successful resolution of immunohistochemistry-confirmed effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir at 4.9-5.6 mg/kg daily for 80 days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35934910",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "uccessful treatment of a South African cat with effusive feline infectious peritonitis with remdesivir.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35934910",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Currently there is no drug proven to effectively treat cats with feline infectious peritonitis (FIP).HYPOTHESIS: Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats with FIP, and increase their quality of life.ANIMALS: Twenty-three privately owned cats with FIP.METHO",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn\u00ae in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34835034",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29778200",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ed, and most of the affected cats die or are euthanized. Anecdotally, doxycycline has been used to treat FIP-affected cats, but there are currently no",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33799985",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " and no relapse was observed.Conclusions and relevance: GS-441524 combined with GC376 can be safely and effectively used to treat FIP and reduces the ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15123155",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study provides a proof of principle for the use of molnupiravir in cats and supports the need for future studies to further evaluate molnupiravir as a potentially safe and effective therapy for FIP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36297266",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Objectives: The main objectives of this study were to investigate the efficacy of the nucleotide analog GS-441524 in combination with the 3C-like protease inhibitor GC376 for the treatment of naturally aquired feline infectious peritonitis (FIP) and to test whether their combination shortens the dosing period and improves the cure rate",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our study suggested that HCQ and rfIFN-\u03c9 are applicable for treatment of FIP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32456286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis (FIP).METHODS: Cats ranged from 3.4-73 months of age (mean 13.6 months); 26 had effusive or dry-to-effusive FIP and five had non-effusiv",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30755068",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34835034",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn\u00ae in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn\u00ae.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34835034",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Feline infectious peritonitis (FIP) is a common and highly lethal coronavirus disease of domestic cats. Recent studies of diseases caused by several RNA viruses in people and other species indicate that antiviral therapy may be effective against FIP in cats. The small molecule nucleoside analog GS-441524 is a molecular precursor to a pharmacologically active nucleoside triphosphate molecule.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29778200",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Prednisolone, immune suppressive drugs, glucocorticoid, Cyclophosphamide, Feline interferon-omega, FeIFN-omega, Propentofylline, PPF, Polyprenyl Immunostimulant, GC376, 3C-like protease (3CLpro) inhibitors, siRNA, viroporin inhibitor, HMA, DIDS, anti-feline TNF-alpha monoclonal antibody, GS-441524, Mutian\u00ae, Xraphconn, (Mutian X), Mefloquine, itraconazole, remdesivir"
}